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Abstract   
Pharmaceutical care (PC) has been shown to improve  the outcome of drug therapy in many disease conditions. 
HIV/AIDS is one of  the  disease conditions that are fraught with many problems that can benefit from this new 
emphasis of pharmacy practice also known as ‘pharmacists care’. Adverse drug reactions or effects are unintended 
and  undesirable  effects  of  drugs  other  than  their  known  and  expected  actions  which  can  be  unpleasant  and 
sometimes fatal. This study is designed to evaluate the impact of pharmaceutical care activities on the occurrence of 
side/adverse drug reactions in HIV/AIDS patients receiving antiretroviral drugs. The components of the American 
society of health-system pharmacists (ASHP) guidelines on ‘standardized method for pharmaceutical care’ was used 
as a data collection instrument to evaluate, document and intervene in the antiretroviral therapy of about  one 
thousand four hundred and seventy three (1,473) patients. The study identified about sixty (60) different types of 
side/adverse effects occurring among these patients through observation and patient complaints. The study also 
showed significant reduction in the incidence of side/adverse drug effects following the Pharmacist’s intervention 
activities,  p  ≥  0.5.    The  study  showed  that  pharmacists’  interventions  in  antiretroviral  drug  therapy  through 
Pharmaceutical  care  can  significantly  reduce  the  incidence  of  side/adverse  drug  effects  in  HIV/AIDS  patients 
receiving antiretroviral drugs. 
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1. Introduction 
Pharmaceutical care (PC) has been defined as the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improves or maintains a patient’s quality of life (Hepler & Strand, 1990) as 
modified  by  (FIP,  1998).  The  concept  of  the  pharmaceutical  care  is  about  pharmacists  taking  more 
responsibility for the outcome of drug therapy. HIV/AIDS on the other hand is possibly the biggest challenge 
facing  the  healthcare  system  today.  It  is  a  condition  that  occurs  when  the  HIV  organism  (a  retrovirus) 
weakens the human immune system. Infection with the virus is a dynamic process characterized by vigorous 
viral replication, CD4 lymphocyte depletion and profound immune deficiency. 
The  concept  and  philosophy  of  pharmaceutical  care  has  been  adopted  and  implemented  in  many 
developed countries for many years now. It has achieved great successes in the care of patients in the US, UK 
and other developed countries of the world as patients in these places now get better care from Pharmacists 
who alongside the patients and healthcare managers are delighted about the initiative (Erah and Nwazuoke, 
2002).  Antiretroviral drug therapy (ART) has faced serious challenges despite much progress and many 
patients  still  do  not  benefit  from  it  due  to  viral  resistance,  adverse  effects  of  chronic  therapy  ,  lack  of 
adherence to complex regimens, unavailability of current agents in the developing countries (where the 
pandemic  has  its  greatest  impact).  The  consequences  of  these  have  been  devastating  to  the  patients, 
healthcare  system  and  many  countries.    Controlling  the  disease  will  involve  ensuring  that  the  patients 
receiving treatment get the maximum benefits of drug therapy. Thus the management of HIV/AIDS infection 
is  one  situation  that  has  brought  to  the  front  burner  the  issue  of  establishing  pharmaceutical  care  in 
healthcare systems [world over] (Obodozie, 2006). Hence the role of the Pharmacist in healthcare through 
the concept of pharmaceutical care has become imperative in the global struggle to save humanity from 
extinction due to HIV/AIDS. 
 
2. Methods 
This is part 1 of  4 from a study carried out using the method described below. The other parts will be 
subsequently published in this journal. Before the study, an application for ethical approval of the study was 
sent to the management of the Federal medical centre Owerri, Imo state, Nigeria where the study was carried 
out and the approval was granted. International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1170-1186 
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The  components  of  the  American  society  of  health-system  pharmacists  (ASHP)  guidelines  on 
‘standardized method for pharmaceutical care’ (ASHP,1996) was used as a data collection instrument to 
evaluate, document and intervene in the antiretroviral therapy of about  one thousand four hundred and 
seventy three (1,473) patients. 
Data was collected from the patients’ prescription sheets, laboratory report forms, care/ART cards, and 
other  relevant  forms  in their  treatment  folders. Other  relevant  information  was  also  obtained  from  the 
patients through oral interview. The data collected at this stage formed the base-line/ pre - intervention data 
for the study. 
After documentation of these base-line data, pharmaceutical care interventions were implemented where 
necessary and this included: 
1.  Patient education using a validated educational material applied uniformly to all the patients in the 
study. 
2.  Healthcare personnel education, counseling and discussions.  
3.  Recommendations for changes of drugs/regimens change of drug dose interval, duration or dosage 
form,  addition  of  more  drugs,  treatment  of  untreated  conditions,  implementation  of  non-drug 
therapy, patient referral.  
4.  Ensuring that patients do their laboratory tests.  
5.  Monitoring the laboratory test results and carrying out interventions where necessary.  
6.  Giving  patients  access  to  pharmacists  any  time  they  needed  it  i.e.  maintaining  constant 
communication between the patients and the pharmacists. 
Then a repetition of the data collection and documentation above was done nine (9) months after the 
implementation of the pharmaceutical care interventions mentioned above. This data represents the post - 
intervention data. The two data sets (baseline / pre-intervention & post-intervention data) were then be 
collated, analyzed and compared to see if the interventions resulted in any significant differences in the 
occurrence of drug therapy problems. Appropriate statistical analysis was also applied to the data using 
Microsoft Excel and SPSS tools. Inclusion and exclusion criteria used for the study were; 
1.  New patients were excluded from the study since they will have had no previous encounter with the 
system and so no existing data on them.  
2.  Patients selected were those who have received treatment, drugs and counseling from the hospital 
for at least nine (9) months (i.e. who have visited the hospital for at least three (3) times). 
3.  Both adults and children as well as males and females were involved in the study.  
4.  Patients whose medications will last for less than three (3) months will be excluded from the study. 
This is to give the interventions enough time to make impacts and produce the possible results and to 
ensure uniformity of treatment duration and contact with the pharmacist in all the participating 
patients. 
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3. Results 
The  study  showed  significant  reduction  in  the  incidence  of  side/adverse  drug  effects  following  the 
Pharmacist’s  intervention  activities.  It  identified about  sixty  (60)  different  types  of  side/adverse effects 
through observation and patient complaints. These included weakness/fatigue, Nausea, Vomiting, Abdominal 
pain, Anorexia (loss Appetite), Sudden weight Loss, Muscle weakness, Jaundice, Skin rashes, Lipodystrophy, 
Extremity  wasting/thin  legs  and  arms,  Facial  thinning,  Increased  urination,  Excessive  thirst/hunger,  
Headaches, Peripheral neuropathy, Dry mouth,  Dizziness,  Insomnia, Nightmares, Anemia, Excessive weight 
gain, Cough, Boils, Cataract, Ovulation irregularities,  Fever, Diarrhea, Palpitation, Watery stool, Pruritus, 
Excessive  sweating,  Salivation,  Tinnitus,  Black  spots  on  skin,  Spots  on  palm  ,  Excessive  sleep,  Visual 
disturbances,  Painful  menstruation,    Loss  of  menstruation,  Internal  heat,  Constipation,    Nail  thickening, 
Breast size increase, Bloating of entire body, Bloating of entire body, Swelling of hands & legs, Dry lips, Palm 
discoloration, Blistered lips, Spots on tongue, Nail discoloration, Restlessness,  increased blood pressure, 
Indigestion,  Tongue swelling, Rigor, Flatulence and Facial swelling. These are shown in tables below; 
 
Table 1. Age distribution 
    Age Range  
Number of Patients 
 
Difference  (A – B)     
 
% of total =  A 
or  
B/T x 100 
Pre - intervention 
evaluation (A) (% of 
total).   
Post - intervention 
evaluation (B) (% of 
total).   
2 yrs – 15 yrs  146  146  0  10 
15 yrs above  1327  1327  0  90 
Total (T)  1473  1473  0  100 
 
 
Table 1 shows that 90% of patients involved in the study were adults (18years and above) while 10% of 
the patients were children (2yrs – 15yrs). 
Table  2  shows  that  most  of  the  patients  in  the  study  were  females  (65%)  while  the  male  patients 
accounted for 35% of the study population. 
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Table 2. Sex (gender) distribution 
 
  
 
 
 
 
 
 
 
 
Table 3. Distribution of drug regimens 
Regimen 
Number of Patients 
  
% of total = A/T  
or  
B/T x 100 
  
Difference 
Pre -intervention  Post - intervention  (A - B) 
evaluation (A) 
(% of total).   
evaluation (B) 
(% of total).      
AZT/3TC/NVP  339  339  0  23.01 
D4T/3TC/NVP  948  948  0  64.3 
AZT/3TC/EFV  36  36  0  2.4 
D4T/3TC/EFV  105  105  0  7.13 
3TC/ABC/NVP  5  5  0  0.34 
LPV+r /TDF+ FTC  11  11  0  0.8 
D4T/3TC/ABC  3  3  0  0.2 
TDF+FTC/LPV+  
r/AZT+3TC  3  3  0  0.2 
TDF+FTC/LPV+  
r/AZT  3  3  0  0.2 
TDF+FTC /NVP  6  6  0  0.41 
AZT+3TC /TDF /LPV+r.  2  2  0  0.14 
TDF+FTC/EFV  11  11  0  0.8 
LPV+r/EFV  1  1  0  0.07 
TOTAL (T)  1473  1473  0  100 
 
Table 3 shows that most of the patients (64.3%) are on the D4T/3TC/NVP regimen while 23.01% of them 
are  on  the  AZT/3TC/NVP  regimen.  Others  are  D4T/3TC/EFV  (7.13%),  TDF+FTC  /  NVP  (0.41%), 
AZT/3TC/EFV  (2.4%),  LPV+r /  TDF+FTC  and  TDF+FTC  /  EFV  (0.8%),  (0.41%),  D4T/3TC/ABC,  LPV+r  / 
sex 
Number of Patients   
Difference 
(A - B) 
 
% of total = A/T  
or  
B/T x 100 
Pre - intervention 
evaluation (A)  
(% of total)  
Post - intervention 
evaluation (B)  
(% of total) 
Male  513  513  0  35 
Female   960  960  0  65 
Total (T)  1473  1473  0  100 International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1170-1186 
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TDF+FTC / AZT and LPV+r / TDF+FTC/AZT+3TC (0.2%), ABC/3TC/NVP (0.34%), TDF/LPV+r / AZT+3TC 
(0.14%) and LPV+r / EFV (0.07). 
 
Table 4. Distribution of frequencies of side effects 
 
S/N 
 
Side Effects 
Frequency  Difference 
(A - B) 
% Difference 
(A-B)/A x 100  Pre-ntervention  
(% of total)  
Post-intervention 
(% of total)   
1  Weakness/fatigue  200(13%)  51(3.2%)  149  75 
2  Nausea   29(2%)  9(0.6%)  20  69 
3  Vomiting   68(4%)  12(0.8%)  56  82 
4  Abdominal pain   62(4%)  21(1.3%)  41  66 
5  Anorexia (loss Appetite)   50(3%)  5(0.3%)  45  90 
6  Sudden weight Loss   20(1%)  3(0.2%)  17  85 
7  Muscle weakness  10(0.6%)  1(0.1%)  9  90 
8  Jaundice  5(0.3%)  0(0%)  5  100 
9  Skin rashes  327(21%)  97(6.1%)  230  70 
10  Lipodystrophy   21(1%)  6(0.4%)  15  71 
11  Extremity wasting/thin 
legs and arms.  1(0.1%)  0(0%)  1  100 
12  Facial thinning   3(0.2%)  1(0.1%)  2  67 
13  Increased urination   10(0.6%)  5(0.3%)  5  50 
14  Excessive thirst/hunger   36(2.3%)  6(0.4%)  30  83 
15  Headaches  102(6.4%)  36(2.3%)  66  65 
16  Peripheral neuropathy   118(7.5%)  41(2.6%)  77  65 
17  Dry mouth   8(0.5%)  2(0.1%)  6  75 
18  Dizziness  182(11.5%)  31(2.%)  151  83 
19  Insomnia   39(2.5%)  19(1.2%)  20  51 
20  Nightmares   15(0.9%)  2(0.1%)  13  87 
21  Anaemia   6(0.4%)  2(0.1%)  4  67 
22  Excessive weight gain   3(0.2%)  1(0.1%)  2  67 
23  Cough   10(0.6%)  2(0.1%)  8  80 
24  Boils   3(0.2%)  0(0%)  3  100 
25  Cataract   2(0.1%)  0(0%)  2  100 
26  Ovulation irregularities   3(0.2%)  0(0%)  3  100 
27  Fever  49(3.1%)  18(1.1%)  31  63 
28  Diarrhoea  4(0.3%)  1(0.1%)  3  75 
29  Palpitation   6(0.4%)  0(0%)  6  100 
30  Watery stool   2(0.1%)  0(0%)  2  100 
31  Pruritus   70(4.4%)  39(2.5%)  31  44 
32  Excessive sweating   4(0.3%)  0(0%)  4  100 
33  Salivation  3(0.2%)  0(0%)  3  100 
34  Tinnitus   6(0.4%)  2(0.1%)  4  67 
35  Black spots on skin   4(0.3%)  2(0.1%)  2  50 
36  Spots on palm    3(0.2%)  0(0%)  3  100 
37  Excessive sleep   3(0.2%)  2(0.1%)  1  33 
38  Visual disturbances   8(0.5%)  3(0.2%)  5  65 International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1170-1186 
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39  Painful menstruation   4(0.3%)  1(0.1%)  3  75 
40  Loss of menstruation   9(0.6%)  3(0.2%)  6  67 
41  Internal heat   16(1%)  7(0.4%)  9  56 
42  Constipation   4(0.3%)  0(0%)  4  100 
43  Nail thickening   3(0.2%)  2(0.1%)  1  33 
44  Breast size increase   2(0.1%)  1(0.1%)  1  50 
45  Bloating of entire body   3(0.2%)  1(0.1%)  2  67 
46  Swelling of hands & legs  4(0.3%)  1(0.1%)  3  75 
47  Dry lips   3(0.2%)  1(0.1%)  2  67 
48  Palm discoloration   2(0.1%)  1(0.1%)  1  50 
49  Blistered lips  3(0.2%)  1(0.1)  2  67 
50  Spots on tongue  2(0.1%)  1(0.1%)  1  50 
51  Nail discolouration   3(0.2%)  1(0.1%)  2  67 
52  Restlessness   4(0.3%)  0(0%)  4  100 
53  Increased blood pressure   7(0.4%)  1(0.1%)  6  86 
54  Indigestion   2(0.1%)  1(0.1%)  1  100 
55  Tongue swelling  2(0.1%)  1(0.1%)  1  50 
56  Rigour   2(0.1%)  1(0.1%)  1  50 
57  Flatulence   6(0.4%)  2(0.1%)  4  67 
58  Facial swelling   7(0.4%)  3(0.2%)  4  57 
Total  1,583  450  1133  72% 
 
Table 4 shows that about 58 different types of side effects were identified. The most prominent of these 
side/adverse effects (and their pre and post - intervention incidence trequences) were skin rashes (21% & 
6%),  weakness/fatigue  (13%  &  3.2%),  dizziness (11.5%  &  2%),  peripheral  neuropathy  (7.5%  &  2.6%), 
headache (6.4% & 2.3%) vomiting (4% & 0.8%), abdominal pain (4% % 1.3%), anorexia/loss of appetite (3% 
& 0.3%), fever (3.1% % 1.1%), insomnia (2.5% & 1.2%), nausea (2% & 0.6%),  Lipodystrophy (1% & 0.4%), 
sudden weight loss (1% & 0.2%), excessive thirst/hunger (2.3% & 0.4%), and pruritus (4.4% & 2.5%). 
Generally, there were 1,583 incidences of side effects prior to interventions. This reduced to 450 incidents 
after the interventions representing a decrease of 72%. 
 
 Table 5. Summary of incidence of side effects 
 
Variable 
No. of patients  Difference 
(A – B) 
% Difference 
(A–B)/A x 100  Pre-intervention  
(% of total)  
Post- intervention  
(% of total) 
No side - effects     705 (48%)  1156 (78%)  451  64 
Experienced side 
effects  768 (52%)  317 (22%)  451  59 
Total   1473  1473  0  0 
 
Table 5 shows that there was a 64% increase in the number of patients not experiencing side effects and a 
decrease of 59% in the number of patients experiencing side effects. International Journal of Development and Sustainability                                                                  Vol.1 No.3 (2012): 1170-1186 
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 Table 6. Distribution of side effects incidence in correlation with drug regimen and gender (single side effect) 
 
S/N 
 
REGIMEN 
MALE  FEMALE 
PRE-
INTERV 
POST - 
INTERV 
DIFF  % DIFF  PRE – 
INTERV 
POST – 
INTERV 
DIFF  % 
DIFF 
1  AZT/3TC/NVP  12  4  8  67  35  24  11  31 
2  3TC/D4T/NVP  69  54  15  22  131  97  34  26 
3  AZT/3TC/EFV  2  2  0  0  1  0  1  100 
4  3TC/D4T/EFV  9  9  0  0  17  17  0  100 
5  LPV+ r/TDF + FTC  2  0  2  100  2  2  0  100 
6  AZT/LPV + r  1  1  0  0  0  0  0  0 
7  TDF + FTC/ NVP  0  0  0  0  1  1  0  0 
8  AZT+3TC/TDF/LP
V+ r 
1  1  0  0  0  0  0  0 
9  TDF + FTC /EFV  1  1  0  0  0  0  0  0 
  Total  97  72  25  26  187  141  46  25 
 
Table 6 shows that 70% of incidence of single side effects occurred in patients of the 3TC/D4T/NVP 
regimen, the AZT/3TC/NVP regimen accounted for 16% of the side effects, the 3TC/D4T/EFV accounted for 
9% of the side effects while the AZT/3TC/EFV accounted for 1% of the side effects. These four regimens 
accounted for 96% of the side effects. Also the side effects occurred more in the females (65%) than in male 
(35%). The table also shows that generally the incidences of these side effects were reduced by 58% from 
534, to 309 cases after the interventions. 
 
 Table 7. Distribution of side effects incidence in correlation with drug regimen and gender (multiple side effects) 
 
S/N 
 
REGIMEN 
MALE  FEMALE 
PRE – 
INTERV. 
POST – 
INTERV. 
DIFF  % 
DIFF 
PRE – 
INTERV. 
POST – 
INTERV. 
DIFF  % 
DIFF 
1  AZT/3TC/NVP  6  1  5  83  34  8  26  76 
2  3TC/D4T/NVP  67  18  49  73  105  48  57  54 
3  AZT/3TC/EFV  2  2  0  0  2  2  0  0 
4  3TC/D4T/EFV  5  5  0  0  18  8  10  56 
5  LPV + r/TDF + 
FTC 
1  1  0  0  4  2  2  50 
6  TDF + FTC/NVP  0  0  0  O  2  0  2  100 
7  TDF + FTC / EFV  3  1  2  67  0  0  0  0 
8  AZT / TDF + FTC 
/  LPV + r 
1  0  1  100  0  0  0  0 
Total    85  28  57  67  165  68  97  59 
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Table 7 above shows the distribution of the incidence of multiple side effects in correlation with drug 
regimen and gender. The trend here is the same as the trend in the distribution for single side affects as 
shown in table 6 above. 
 
 Table 8. Combination of Tables 6 & 7 (single plus multiple side effects) 
 
S/N 
 
REGIMEN 
MALE  FEMALE 
PRE – 
INTERV. 
POST – 
INTERV. 
DIFF  % 
DIFF 
PRE – 
INTERV. 
POST – 
INTERV. 
DIFF  % 
DIFF 
1  AZT/3TC/NVP  18  5  13  72  69  42  27  39 
2  3TC/D4T/NVP  136  72  64  47  236  145  91  39 
3  AZT/3TC/EFV  4  4  0  0  3  2  1  33 
4  3TC/D4T/EFV  14  14  0  0  35  25  10  29 
5  LPV + r/TDF + FTC  3  1  2  67  6  4  2  33 
6  AZT/ LPV + r/ TDF 
+ FTC 
2  1  1  50  0  0  0  0 
7  TDF + FTC/NVP  0  0  0  0  1  1  0  0 
8  AZT+3TC/TDF/LPV 
+ r 
1  1  0  0  0  0  0  0 
9  TDF + FTC /EFV  4  2  2  50  0  0  0  0 
Total    182  100  82  45  352  209  143  41 
 
Table 8 is combination of table 6 and 7 above to give an overall picture of the correlation of side/adverse 
effects with drug regimen and gender. 
 
 Table 9. Distribution of side effect incidence in correlation with drug regimen and age (single side effect) 
 
S/N 
 
REGIMEN 
CHILDREN  ADULT 
PRE  – 
INTERV. 
POST  – 
INTERV. 
DIFF  % DIFF  PRE  –
INTER
V. 
POST  – 
INTERV. 
DIFF  % 
DIFF 
1  AZT/3TC/NVP  5  4  1  20  42  24  18  43 
2  3TC/D4T/NVP  11  6  5  45  186  145  41  22 
3  AZT/3TC/EFV  0  0  0  0  2  2  0  0 
4  3TC/D4T/EFV  0  0  0  0  28  26  2  7 
5  LPV + r/ TDF + FTC  0  0  0  0  2  2  0  0 
6  AZT/LPV + r/ TDF + 
FTC 
0  0  0  0  1  1  0  0 
7  TDF + FTC/NVP  0  0  0  0  1  1  0  0 
8  AZT+3TC/TDF/LPV+
r 
0  0  0  0  1  1  0  0 
9  TDF + FTC /EFV  0  0  0  0  1  1  0  0 
Total    16  10  61  38  264  203  61  23 
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Table 9 shows the distribution of the incidence of single side effects correlated with drug regimen and age. 
The trend is the same as the trend tables 6 and 7above in terms of incidence per regimen. However most of 
the side effects occurred in adults (95%) while the paediatric cases accounted for only 5% of the side effects. 
 
 Table 10. Distribution of side effect incidence in correlation with drug regimen and age (multiple side effects) 
 
S/N 
 
REGIMEN 
CHILDREN  ADULT 
PRE – 
INTERV. 
POST –
INTERV. 
DIFF  % DIFF  PRE – 
INTERV. 
POST – 
INTERV. 
DIFF  % 
DIFF 
1  AZT/3TC/NVP  4  2  2  50  36  7  29  81 
2  3TC/D4T/NVP  8  1  7  88  169  66  8  61 
3  AZT/3TC/EFV  0  0  0  0  3  3  0  0 
4  3TC/D4T/EFV  0  0  0  0  23  13  10  43 
5  LPV + r/TDF + 
FTC 
0  0  0  0  5  3  2  40 
6   AZT / LPV +  r /  
TDF + FTC 
0  0  0  0  2  0  2  100 
7  TDF + FTC / NVP  0  0  0  0  3  1  2  67 
8  TDF + FTC / EFV  0  0  0  0  1  0  1  100 
Total    12  3  9  75  242  93  149  62 
 
Table 10 shows the distribution of the incidence of multiple side effects as correlated with drug regimen 
and age. The trend is the same as the trend in the distribution for single side effects in table 9 above. 
 
 Table 11. Combination of tables 9 & 10 (single plus multiple side effects) 
 
S/N 
 
REGIMEN 
MALE  FEMALE 
PRE - 
INTER 
POST - 
INTER 
DIFF  % DIFF  PRE – 
INTER 
POST - 
INTER 
DIFF  % DIFF 
1  AZT/3TC/NVP  9  6  3  33  78  31  47  60 
2  3TC/D4T/NVP  19  7  12  63  355  211  144  41 
3  AZT/3TC/EFV  0  0  0  0  5  5  0  0 
4  3TC/D4T/EFV  0  0  0  0  51  39  12  24 
5  LPV + r/TDF + FTC  0  0  0  0  7  5  2  29 
6  AZT/LPV+r/TDF+ FTC  0  0  0  0  1  1  0  0 
7  TDF + FTC/NVP  0  0  0  0  3  1  2  67 
8  AZT  +  3TC/TDF/LPV  + 
r 
0  0  0  0  1  1  0  0 
9  TDF + FTC /EFV  0  0  0  0  4  2  2  50 
Total    28  13  15  54  506  296  210  42 
Table  11  is  combination  of  table  9  and  10  above  to  give  an  overall  picture  of  the  correlation  of 
side/adverse effects occurrence with drug regimen and age. 
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 Table 12. Summary of side effects in correlation with gender and age 
PRE - INTERVENTION  POST - INTERVENTION 
Male  Female  Male  Female 
182 (35%)  352(65%)  100 (32%)  209 (68%) 
PRE - INTERVENTION  POST - INTERVENTION 
Children  Adult  Children  Adult 
28 (5%)  506 (95%)  13 (4%)  296 (96%) 
 
Table 12 shows an abstract summary from Tables 8 and 11. 
 
4. Statistical analysis 
4.1. Hypothesis 
H0:  Pharmaceutical care interventions do not reduce  the occurrence of side/ adverse drug reactions in 
patients receiving antiretroviral drugs. 
Ha:  Pharmaceutical care interventions reduce the occurrence of side/ adverse drug reactions in patients 
receiving antiretroviral drugs. 
Here we use a summarized form of table 4 shown below for statistical analysis using the Pearson’s chi 
square (goodness of fit) test so as to validate the result of the foregoing study. 
 
 
S/N 
 
Total no of side effects 
Frequency 
Difference 
(A - B)  % Difference (A-B)/A x 100  A = Pre-
intervention 
(% of total) 
B = Post-
intervention  
(% of total) 
1  58  1583  450  1133  72 
 
Here the expected frequency (Fe) is 50/50 because the chance probability is half (1/2) since we are 
looking at two groups of data in the table. These are the pre  – intervention frequency (1583) and post – 
intervention frequency (450). 
 
5. Decision rule 
Accept null hypothesis if the value of the chi - square calculated is less  than the chi - square table value and 
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calculated is greater than the chi - square table value and reject the null hypothesis. Mathematically, the 
above decision rule is stated as follows: 
Accept Ho if X2 (Cal) < X2 (tab). 
Accept Ha if X2 (Cal) > X2 (tab).   
As such, 
       
          
  
 
where   Fo = Observe frequency 
         Fe = Expected frequency 
Thus, 
       
            
  
 
           
  
                                     
                                                            
Now, degree of freedom (Df) = (R – 1) (C – 1) 
                      = (2 – 1) (2 – 1)  
                      = (1) (1)  
                      = 1  
Then from Chi-square table,  
Df 1 at 95% confidence level = 3.84  
Thus, we now have  
  X2 cal = 50,201.78 and  
  X2 tab = 3.84 
Therefore based on our chi - square decision rule above, we reject Ho and accept Ha since X2 cal > X2 tab 
and conclude that Pharmaceutical care interventions reduce the occurrence of side/adverse drug reactions in 
patients receiving antiretroviral drugs. 
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6. Discussion 
A very important discovery of the study is that 52% of the patients experienced and complained of one side 
effect or the other. This number was reduced to 22% after the intervention activities.  About sixty (60) 
different types of side effects were identified during the study as shown in table 4 above. Earlier reports 
portrayed the general incidence of side effects as being below 5%. This has now been shown to be different 
for patients on chronic anti - infective therapy like antiretroviral drug therapy. Worthy of note also is the fact 
that the pharmacist intervention activities impacted greatly on the incidence of these side effects reducing 
the number experiencing them by 30%. 
A correlation of the incidence of side effects with the corresponding drug regimen and sex (gender) 
showed that most of the side effects (70%) occurred in patients on the 3TC/D4T/NVP regimen followed by 
the  AZT/3TC/NVP  regimen  (16%),  D4T/3TC/EFV  regimen  (9%)  and  AZT/3TC/EFV  regimen  (1%).  This 
trend was the same in both the patients experiencing single side effect and those experiencing multiple side 
effects. These four (4) regimens accounted for 96% of the side effects. Also the side effects occurred most in 
the female (65%) than in the males (35%). The interventions impacted positively on the incidence of these 
side effects as the number of patients experiencing them reduced by 58% to 309 from 534. 
Another correlation of the incidence of side effects with drug regimen and age corroborated the above 
incidence pattern with the regimen. The 3TC/D4T/NVP regimen had the highest incidence of 70% followed 
by the AZT/3TC/NVP regimen (16%), D4T/3TC/EFV (9%) and AZT/3TC/EFV (1%). Also the side effects 
occurred more in adults (95%) with only 5% of the incidence occurring in children. The low incidence of side 
effects in the children may be attributed to the fact that many of them could have been too tender to know 
and detect the occurrence of these in them. 
Also  the  high  incidence  of  these  side  effects  in  women  can  be  attributed  to  their  physiological 
configuration as they usually have more fatty/adipose tissue into which most of these drugs are distributed. 
They are also less tolerant to pain and discomfort and so may complain of these discomforting side effects 
more than the stronger and more resilient men. The high incidence with the 3TC/D4T/NVP regimen may be 
attributed to the stavudine component which is now being withdrawn from the Nigerian market and being 
replaced with zidovudine where appropriate. Also implicated is nevirapine which is known to cause skin 
rashes in many patients and thus is being considered for withdrawal and replacement with efavirenz. This 
consideration is being weighed carefully as Efavirenz has its problem of CNS problems including nightmares, 
hallucinations, insomnia and suicidal ideation. These improvements were significant at p>0.5 as shown in the 
statistical analysis above. 
 
7. Conclusion 
Based on the results of the study, we conclude that pharmacists’ interventions in antiretroviral drug therapy 
through Pharmaceutical care can significantly reduce the incidence of side/adverse drug effects in HIV/AIDS 
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8. Recommendations 
Based on the results of the study above, the following policy measures are proffered. 
1.  Efforts  should  be  made  to  increase  the  enrollment  and  care  of  children  as  the  number  of  them 
enrolled is far below the number affected by the disease. 
2.  Efforts should also be made to encourage male enrollment since the number enrolled is far below 
that of females indicating a possible shortfall in their enrollment. 
3.  Patients should also be educated on the need to report side/adverse effect as well as other problems 
they may encounter in the course of treatment. 
4.  To be able to achieve the laudable goals of healthcare, adequate manpower should be made available. 
As such government should make effort to train and employ more healthcare workers especially 
pharmacists whose numbers in hospitals are too small compared to the number of patients that need 
their attention. 
5.  Finally,  the  role  of  the  pharmacist  in  patient  care  can  no  longer      be  over  emphasized.  As  such 
government should make adequate efforts to develop and utilize the abundant skills and potentials of 
pharmacist and pharmaceutical care. 
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Appendix C. Chi – square distribution table 
 
 
 
 
 